University of Toronto agrees to drop objections to proposed Connaught acquisition by French vaccine developer Institut Merieux, which will grant the university $9 mil. (Canadian) for vaccine research and an additional C $6 mil. to other Canadian institutions. The deal represents a substantial increase over an existing agreement in which the university received C $400,000 from Connaught in 1988. On Oct. 27, Institut Merieux extended its C $37 per share offer for Connaught stock. Ciba-Geigy and Chiron, which have an outstanding offer for Connaught of C $30 per share, also presented a similar investment agreement to the university. Ontario Supreme Court said Oct. 27 that it is delaying ruling on university's lawsuit against Connaught because of the agreement-in-principle reached in the dispute....
You may also be interested in...
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
FDA and CDC advisory committee members wonder how to use the single-shot J&J vaccine if an ongoing study shows two doses are better than one.